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Background: It is well established that vaccination of humans and transgenic animals against fibrillar Aβ prevents
amyloid accumulation in plaques and preserves cognitive function in transgenic mouse models. However,
autoimmune side effects have halted the development of vaccines based on full length human Aβ. Further
development of an effective vaccine depends on overcoming these side effects while maintaining an effective
immune response.
Results: We have previously reported that the immune response to amyloid oligomers is largely directed against
generic epitopes that are common to amyloid oligomers of many different proteins and independent of a specific
amino acid sequence. Here we have examined whether we can exploit this generic immune response to develop a
vaccine that targets amyloid oligomers using a non-human random sequence amyloid oligomer. In order to study
the effect of vaccination against generic oligomer epitopes, a random sequence oligomer (3A) was selected as it
forms oligomers that react with the oligomer specific A11 antibody. Oligomer mimics from 3A peptide, Aβ, islet
amyloid polypeptide (IAPP), and Aβ fibrils were used to vaccinate Tg2576 mice, which develop a progressive
accumulation of plaques and cognitive impairment. Vaccination with the 3A random sequence antigen was just as
effective as vaccination with the other antigens in improving cognitive function and reducing total plaque load (Aβ
burden) in the Tg2576 mouse brains, but was associated with a much lower incidence of micro hemorrhage than
Aβ antigens.
Conclusion: These results shows that the amyloid Aβ sequence is not necessary to produce a protective immune
response that specifically targets generic amyloid oligomers. Using a non-human, random sequence antigen may
facilitate the development of a vaccine that avoids autoimmune side effects.* Correspondence: cglabe@uci.edu
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Alzheimer's disease (AD) is associated with progressive
cognitive decline, neuronal loss and the accumulation of
senile plaques and neurofibrillary tangles in affected
regions of the brain [1]. The original amyloid cascade
hypothesis [2,3] proposed that the accumulation of
amyloid plaques was the principal factor in AD patho-
genesis. However recent studies indicate that small sol-
uble Aβ aggregates or oligomers may represent the
primary pathogenic entities [4-9]. One of the first tests
of the therapeutic value of preventing the accumulation
of Aβ or facilitating its clearance came from studies by
ELAN, who immunized transgenic mouse models of AD
with Aβ42 fibrils (fAβ42) [10]. Immunization with fAβ42
(AN1792) results in a nearly complete absence of Aβ
plaque deposits, both in mice that were vaccinated prior
to the onset of amyloid deposition and in animals that
were vaccinated after amyloid deposition was well
underway. However, human clinical trials were halted
due to a high incidence of meningioencephalitis that is
presumably due to an auto inflammatory reaction to
immunization with human Aβ. Overcoming the auto in-
flammatory side effects while maintaining an effective
immune response is a hurdle that must be overcome for
the development of a human vaccine for AD [11].
We have previously shown that vaccination of trans-
genic mouse models of amyloid deposition with an Aβ
oligomer mimic antigen is just as effective in reducing
amyloid deposition and preventing cognitive dysfunction
as vaccination with human fAβ42 [12]. The immune
response to this oligomer mimic antigen results in the
production of antibodies that recognize generic epitopes
in prefibrillar oligomers independent of the precise
amino acid sequence. Indeed, vaccination of rabbits with
islet amyloid polypeptide (IAPP) oligomer mimics results
in the production of an immune serum that specifically
recognizes a variety of prefibrillar amyloid oligomers but
not fibrils and is indistinguishable from the serum pro-
duced in response to vaccination with Aβ oligomer
mimics [13]. This indicates that vaccination with the
prefibrillar oligomer (PFO) conformation of other pep-
tides gives rise to antibodies that recognize Aβ PFOs,
suggesting that vaccination with a non-human random
peptide sequence that also forms PFOs would also give
rise to this generic PFO specific immune response.
Recently, it was reported that vaccination of Tg mice
with a 13 residue random sequence peptide derived from
the carboxyl terminus of pABri (polymerized British
amyloidosis peptide) related peptide reduces amyloid
pathology and preserves cognitive function in APP/PS1
transgenic mice [14]. Here we report that vaccination
with a random sequence PFO antigen gives rise to a gen-
eric PFO specific immune response that recognizes Aβ
oligomers and that vaccination of Tg mice with thisantigen is as effective in reducing amyloid deposition
and preserving cognitive function. The use a non-human
amyloid oligomer as a vaccine may overcome potential
problems with auto inflammatory side effects observed
with human Aβ.
Results
Identification of a random peptide sequence that forms
A11 positive prefibrillar oligomers
We synthesized a series of 20 random sequence peptides
from a restricted set of 8 amino acids and tested their
ability to form prefibrillar oligomers by dot blot analysis
with A11. Of these peptides, only 10 were sufficiently
soluble to work with. One of these sequences, 3A,
formed oligomers that react strongly with A11. We pre-
pared 3A oligomer mimetic antigen by coupling 3A to
colloidal gold particles and vaccinated rabbits with this
immunogen. Serum from 3A vaccinated rabbits and A11
was used to probe dot blots containing Aβ monomer, Aβ
prefibrillar oligomers, Aβ fibrils, calcitonin prefibrillar oli-
gomers, IgG light chain prefibrillar oligomers and syn-
thetic KK(Q40)KK prefibrillar oligomers. Like A11, which
is raised against Aβ oligomer mimic antigen, serum from
3A vaccinated rabbits reacted with all prefibrillar oligomer
samples, including Aβ, but not Aβ monomer or Aβ fibrils
(Figure 1). No immunoreactivity was observed for preim-
mune serum from the rabbit immunized with 3A oligo-
mers. These results demonstrate that vaccination with a
non-human random peptide sequence oligomer mimic
give rise to an immune response that recognizes many
different types of prefibrillar oligomers, including Aβ and
are consistent with our previous observations that serum
from rabbits vaccinated with IAPP oligomer mimics is
indistinguishable from A11 [13].
Immune response in Tg2576 mice vaccinated with
prefibrillar oligomer mimics and fibrillar Aβ
To evaluate the therapeutic effectiveness of the 3A anti-
gen, we immunized Tg2576 mice with 3A, Aβ, and IAPP
oligomer mimetics and Aβ fibrils. Mice were immunized
at monthly intervals beginning at 3 months up to
14 months. We performed ELISA assays to analyze the
reactivity of the sera obtained from all groups of immu-
nized mice against monomeric Aβ, Aβ PFOs, IAPP
PFOs, 3A PFOs and Aβ fibrils (Figure 2). For all vacci-
nated groups, the highest reactivity is observed for the
antigen they were immunized with. In addition, generic
reactivity for prefibrillar oligomers samples is observed
in the groups immunized with prefibrillar oligomer
mimics. The immune response to the 3A peptide oligo-
mer vaccine was specific for prefibrillar oligomers and
did not display significant reactivity to monomeric or
fibrillar Aβ (Figure 2). In contrast, the serum from Aβ
fibrillar vaccinated mice shows immunoreactivity with
Figure 1 Immune response to 3A oligomer mimics. Serum
from A11 vaccinated rabbits and 3A was used to probe dot blots
containing Aβ monomer (1), Aβ prefibrillar oligomers (2), Aβ fibrils
(3), calcitonin prefibrillar oligomers (4), IgG light chain prefibrillar
oligomers (5) and synthetic KK(Q40)KK prefibrillar oligomers (6).
It was observed that serum from 3A vaccinated rabbits reacted
with all prefibrillar oligomer samples like A11 serum, but not Aβ
monomer or Aβ fibrils. There was no immunoreactivity when using
pre-immune serum.
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immunization with Aβ fibrils produced antibodies that
reacted primarily with their own antigen and displayed
some cross-reactivity with Aβ PFOs. Cross-reactivity
could be due to small quantities of fibril-like structures
in the PFO sample or small amounts of antibodies
against PFOs in the serum. The titer of each vaccinated-
group is expressed as the log10 of the IC50 values to
normalize the distribution and statistical analysis on the
transformed values has been done accordingly. As a re-
sult all the vaccinated groups, including IAPP oligomer,showed a significant immune response not only against
their own antigen, but also against oligomers as com-
pared to non-vaccinated mice. Control vaccinated mice
displayed very low titers (<50) towards all antigens.
None of the mice developed significant quantities of
antibodies that react with Aβ40 monomer. These results
indicate that the antibodies developed by the immunized
mice in response to both Aβ fibrils and oligomers are
predominantly conformation-dependent, aggregation
specific and recognize generic epitopes that are inde-
pendent of the precise amino acid sequence.
Vaccination with 3A oligomer mimics improves
cognitive performance
We evaluated the reference memory of Tg2576 mice at
the age of 14 months in a Morris water maze test. At
the age of 14 months, mice were trained on the spatial
reference version of the Morris water maze task after
11 months of vaccination. 3A peptide, Aβ oligomer, Aβ
fibril and IAPP oligomer vaccinated mice all demon-
strate a significant improvement (***p < 0.001) in behav-
ioral acquisition and retention in Morris Water Maze
(Figure 3A). At 90 minutes and 24 h in probe trials with
the platform removed, mice immunized with Aβ oligo-
mer, IAPP oligomer, 3A oligomer mimics and Aβ fibrils
show significant improvement (***p < 0.001) in memory
retention on the latency to cross the platform location
and the number of platform crosses during 90 minute
and 24 h tests as compared to controls (Figure 3B). Con-
textual learning and memory was evaluated using the
passive inhibitory avoidance task (Figure 3C). Passive
avoidance memory retention (mean ± S.E.M.) as mea-
sured by the ability of mice to remember an electrical
shock after 24 hrs. Passive-avoidance tests were carried
out in Tg2576 mice at 14 months of age. In the first ac-
quisition trial of the learning stage, all mice (14 months
old) entered the dark compartment immediately after
being placed in the illuminated compartment. In reten-
tion trials the step-through latency of the immunized
mice with Aβ oligomer, IAPP oligomers and 3A oligo-
mer mimics was significantly increased (*p < 0.05 for Aβ
oligomer and ***p < 0.001 for IAPP and 3A peptide, ) as
compared to that of the control immunized group
(Figure 3C). We evaluated visual recognition memory at
the ages of 14 months in a novel object recognition test
(Figure 3D). This test is believed to be primarily
dependent on cortex. The time that the mice explored the
novel object versus the familiar object is called the recog-
nition index (RI). 50% RI means that mice are not specific-
ally interested in either of the objects. At 14 months,
Tg2576 mice immunized with 3A oligomer mimics vacci-
nated mice shows statistically significant improvement in
novel object recognition memory at both 1.5 hrs and
24 hrs (3D), to control vaccinated mice (*p < 0.05).
Figure 2 Characterization of the immune response in vaccinated Tg2576 mice. Antibody titers against Aβ monomer, Aβ prefibrillar
oligomer, IAPP prefibrillar oligomer, Aβ fibril and 3A prefibrillar oligomer were determined for all the vaccinated groups by ELISA. Each vaccinated
group showed significant immune response against its respective antigen as compared to the control vaccinated group. Values represent the
average titer (mean± SD) from the sera of 6 individual mice in each group (**p < 0.01).
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plaque accumulation in Tg2576 mice
Vaccination against fibrillar Aβ is known to reduce
plaque deposition in transgenic animals [10]. AmyloidFigure 3 Vaccination with 3A oligomer improves spatial cognitive de
groups of Tg2576 mice were evaluated using a spatial reference paradigm
gold and adjuvant. Mice were trained on the spatial reference version of th
Aβ oligomer-, IAPP oligomer- and Aβ fibril-vaccinated mice also showed si
vaccinated mice (Figure 1A). B. In probe trial during 1.5 hr and 24 hr testin
than control vaccinated Tg2576 mice (ANOVA, ***p < 0.001, **p < 0.01 and
mainly amygdala-dependent task. Mice were tested for retention of memo
taken out after 180 s if they did not cross over. At 24 hrs all the vaccinated
**p < 0.01 for Aβ fibril, Aβ oligomer and IAPP oligomer vaccinated mice). D
vaccinated Tg2576 mice are impaired, spending an equivalent amount of t
showed improvement as compared to control vaccinated (*p < 0.05).deposition in 14 months Tg2576 mice was assessed using
the human Aβ specific monoclonal antibody, 6E10.
We compared the effectiveness of the immunization
on amyloid deposition by quantifying the amount officits in Tg2576 mice. A. 3A peptide-vaccinated and other vaccination
and compared with control treated mice vaccinated with colloidal
e Morris water maze task after treatment. Besides 3A oligomer- also
gnificant improvement (***p < 0.001) as compared to control
g, all vaccinated Tg2576 mice also display significantly shorter latencies
*p < 0.05). C. Vaccination prevents contextual fear memory deficits in a
ry for fear-associated environments 24 hrs after training. Mice were
mice showed significant improvement (***p < 0.001 for 3A vaccinated,
. Context dependent object recognition testing reveals that control
ime exploring both objects. At 14 months all the vaccinated mice
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show representative photomicrographs from the hippo-
campus and cortex of control and immunized animals.
Image analysis of sections from multiple animals demon-
strated that Aβ deposits in Aβ oligomer, IAPP oligomer,
3A oligomers mimics and Aβ fibril immunized mice
were decreased significantly as compared to control vac-
cinated group. (Figure 4B) shows that all the immunized
groups displayed a significant reduction in Aβ plaque
load in both hippocampus and cortex as compared to
the respective controls (*p < 0.05, **p < 0.01).
Immunization with 3A oligomer mimics reduces
soluble and insoluble levels Aβ40 and Aβ42
To evaluate whether vaccination with 3A peptide
oligomer not only reduced plaque load but also
affected cerebral total Aβ levels, brain homogenates
were processed to prepare insoluble amyloid deposits.
Subsequently, Aβ levels were quantified using a high-
sensitivity sandwich ELISA measuring Aβ40 and Aβ42
separately as described in methods. Consistent with
the reduced plaque by 3A oligomer mimics, we observed
a significant reduction in soluble and insoluble levels ofFigure 4 Immunization initiated at 3 months of age in Tg2576 anima
photomicrographs of sections from brains (hippocampus and cortex) of 14
Aβ fibril) that have been vaccinated as described in materials & methods fr
with the human amyloid peptide). Scale bar: 100 microns B. Quantitation o
immunoreactivity in hippocampus and cortex of immunized animals at 3–1
value for each animal was determined as the average of 2 sections (except
section (most to all of the area of the section was analyzed). Bars represent
n = 8, IAPP oligomer n = 8, 3A oligomer mimic n = 8 and Aβ fibril n = 6, *p <Aβ40 and Aβ42 (Figure 5). In Aβ fibril vaccinated mice,
the insoluble levels of Aβ40 were not significantly
decreased as compared to other groups, where as insol-
uble Aβ42 levels were significantly decreased.
Immunization with the 3A peptide oligomer mimic anti-
gen induces an immune response that significantly
reduced insoluble levels of cerebral Aβ40 and Aβ42.
Immunization with 3A Oligomer mimics reduces
microglial activation
Microglia play a major role in regulating homeostasis in
the brain and have the ability to activate phagocytose,
secrete cytokines, and to present antigens to T cells
depending on their stimulatory environment [15]. How-
ever, some of these same neuroprotective functions are
detrimental if dysregulated [16]. One of the main charac-
teristics accompanying accumulation of Aβ plaques in
both human Alzheimer’s brain and transgenic mouse
models of AD is an enhanced neuroinflammatory
response characterized by activation of microglia. It has
been previously reported that immunization with Aβ
reduces the microglial activation [12]. We assessed
the effect of immunization by 3A oligomer mimics onls decreases total amyloid deposits. A. Representative
months Tg2576 (Control, Aβ oligomer, IAPP oligomer, 3A peptide and
om 3 to 14 months of age immunostained with 6E10 (which reacts
f plaque load. Image analysis (% Field area) of Aβ (6E10 antibody)
4 months is expressed as % of untreated control mice. The mean
untreated control which is 1 section per animal) using 4–8 images per
group mean± SEM of n mice per group: Control n = 8, Aβ oligomer
0.05 and **p < 0.01 by ANOVA (B).
Figure 5 Vaccination with 3A oligomer mimic strongly reduces levels of Aβ40 and Aβ42 in brain. Following 3–14 months of treatment,
levels of soluble and insoluble levels Aβ40 and Aβ42 on homogenates of the whole brain hemisphere of Tg2576 mice were determined by
ELISA. 3A peptide treatment waswas associated with significantly lower levels of both soluble and insoluble Aβ40 and Aβ42. The insuluble levels
were represented in pg/mg of tissue. Error bars represent standard errors of the mean (n = 8). *p < 0.05 for soluble levels of Aβ40, *p < 0.01 for
soluble and insoluble levels of Aβ42, by one-way ANOVA test.
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histochemistry (Figure 6A). All the immunized groups
displayed a significant decrease in CD45 immunostain-
ing relative to the respective controls (***p < 0.001)
(Figure 6B).
GFAP reactivity is decreased in 3A oligomer mimics
vaccinated mice
Activation of astrocytes is another characteristic feature
of amyloid deposition. It has been observed that acti-
vated astrocytes are reduced in the same proportion as
the amyloid by immunization with Aβ [12]. To assess
the involvement of activated astrocytes following vaccin-
ation, immunohistochemical analysis of GFAP, a marker
for astroglia was performed. Quantitative analysis
showed that there was a significant reduction in GFAP
immunoreactivity. 3A peptide oligomer mimic immu-
nized mice display a significant reduction of activated
astrocytes in the hippocampus and cortex (Figure 7A-J).
The quantification was statistically significant as com-
pared to controls (*p < 0.05). Activated astrocytes were
also significantly decreased in hippocampus of micevaccinated with Aβ oligomer and IAPP oligomer, how-
ever in cortex there was no significant decrease. The ex-
planation for this difference may be that in Aβ oligomer
and IAPP oligomer vaccinated mice where we observed
a decrease in cortical plaques, there is GFAP immunor-
eactivity that is not associated with plaques.
Microhemorrhage is reduced in 3A oligomer
mimics and IAPP oligomer vaccinated mice
An increased incidence of micro hemorrhage has been
observed in both active and passive Aß immunotherapy
[17]. We therefore investigated the incidence of micro
hemorrhage in the vaccinated and control animals. The
method we used categorizes micro hemorrhages in 4 dif-
ferent stages of increasing size and vessel involvement
[18]. The number of micro hemorrhages per section is
reported in Table 1 for each stage. As previously
reported, most of the micro hemorrhages observed in
Aß vaccinated Tg2576 animals were stage 1, consisting
of 1 to 5 grains of iron or small vessel involvement and
are shown in Figure 8A. We found that the 3A and IAPP
vaccinated mice showed a striking reduction in
Figure 6 Vaccination of animals at 3–14 months with antigens decreases anti CD45 reactivity. A. Following vaccination with 3A oligomer
mimics significantly reduces the activated microglia. Representative photomicrographs of CD45 (brown) staining of brain sections from
14 months Tg2576 control, or vaccinated with Aβ oligomer, Aβ fibril, IAPP oligomer and 3A peptide. Scale bar 50 microns. B. Quantitation of
CD45 immunoreactivity in cortex and hippocampus of animals immunized at 3–14 months. Mean of each animal is the average of two sections
in which most to all the area of study was analyzed (4–8 images per section) Bars represent mean± SD of n mice per group. *p < 0.02; CD45:
Control n = 4, Aβ oligomer vaccinated n= 4, Aβ fibril vaccinated n= 4, IAPP oligomer vaccinated n= 4, 3A oligomer mimics vaccinated n = 4 ***
p < 0.001.
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cidence of micro hemorrhages compared to the Aβ
oligomer and Aβ fibril vaccinated groups (***P < 0.001)
(Figure 8B). The 3A and IAPP vaccinated groups were
not statistically different from the control vaccinated
group. Stage 2 micro hemorrhages, consisting of mul-
tiple grains of iron and micro vessel involvement were
also significantly elevated in the Aß fibril and Aß
oligomer vaccinated groups (Table 1, P < 0.001, P < 0.05
respectively). Stage 3 micro hemorrhages, consisting of
several positive micro vessels in 1 area, were signifi-
cantly elevated only in the Aß fibril vaccinated group.
Stage 4 micro hemorrhages with large blood vessel in-
volvement were rarely observed in the Aß vaccinated
groups and none were observed in the control, 3A and
IAPP vaccinated groups although this difference did
not reach statistical significance. In Aß vaccinated fibril
and oligomer groups, micro hemorrhages were
observed in the somatosensory and auditory cortices,
the CA1, CA3 and dente gyrus of the hippocampus,
lateral and ventral hypothalamic areas, and the ventral
posterior medial thalamic nucleus. No preferential
localization of micro hemorrhages in a specific
brain area was observed for any groups. These results
indicate that the non-Aβ antigens may have a better
safety profile with respect to micro hemorrhage than
Aβ containing antigens.Discussion
Anti-Aβ immunotherapy is currently one of the lead-
ing strategies for AD therapeutic development with sev-
eral vaccines in human clinical trial [2,19]. Numerous
pre-clinical studies with mouse models of AD have
demonstrated the ability of Aβ vaccination to prevent
amyloid deposition in the brain. Thus, active immuni-
zation with Aβ [10,20], as well as passive immunization
[15-17,19-27] resulted in a reduction of the amyloid
burden in the brain. Importantly, active immunization
prevented cognitive decline [28,29] and passive immuni-
zations were shown to reverse the memory loss in aged
Tg2576 mice [30]. While these and other studies did not
report any adverse events in AD transgenic mouse mod-
els immunized with fibrillar Aβ42, data from the
AN1792 vaccine trial reported meningoencephalitis in
6% of the patients. These adverse reactions to Aβ42-
immunotherapy appear not to be due to the humoral
antibody response, but rather to the cell-mediated auto-
immune response which induced a Th1 type immune
response in patients that received the AN1792 vaccine
[31-37]. Thus, the goal of this pre-clinical study was to
investigate the effectiveness of a non human random pep-
tide (oligomer mimic), that induces a Th2-type humoral
immune response specific to oligomeric Aβ peptide, but
would not be expected to cause Th1 auto inflammatory
side effects because the antigen is non-human.
Figure 7 Activated astrocytes surrounding Aβ plaques are decreased in Tg2576 mice following vaccination. Astrocyte reactivity (GFAP,
red) preferentially associates with Aβplaques (6E10, green) and is reduced in the hippocampus (A–E) and cortex (F–J) of Tg2576 mice following
immunization with PBS control (A, F), 3A oligomer mimics (B, G), Aβ fibrils (C, H), Aβ oligomers (D, I), and IAPP oligomers (E, J). Cell nuclei were
stained with DAPI (blue). Scale bar = 100 μm. Quantifications of GFAP immunoreactivity in the hippocampus (K) and cortex (L) demonstrate
significant astrocytosis reduction in mice vaccinated with 3A and Aβ fibrils. Error bars represent standard errors of the mean (n = 3). *p < 0.05, **
p < 0.001 by one-way ANOVA test.
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with non-human 3A amyloid random sequence oligomer
produces an efficacious immune response in a murine
model of AD that is comparable to that of mice immu-
nized with fibrillar Aβ42 and Aβ40 oligomer mimics.
We tested escape latency, number of platform crosses in
the Morris water maze test (MWM) (which is related to
hippocampus), novel object recognition (which is related
to cortex) and inhibitory avoidance (which is related to
amygdala). It was found that at 14 months, 3A oligomer
mimic vaccinated mice have a significant improvement
in cognitive function compared to controls. We exam-
ined the effect of immunization on the neuropathologyTable 1 Microhemorrhage foci observed per section
Group Stage 1 Stage 2 Stage 3 Stage 4
Control 0.9 0.5 0 0
3A 1.7 0.2 0 0
IAPP 1.0 0.1 0 0
Aß oligomer 6.9*** 1.6* 0.6 0.4
Aß fibril 7.6*** 2.5*** 0.9*** 0.3
Statistical significance in comparison to control, 3A and IAPP groups:
*** P < 0.001.
* P < 0.05.in 14 months old mice, and showed a significant reduc-
tion in plaques in both cortex and hippocampal region
immunized with 3A peptide. The ELISA data shows that
the reduction in insoluble Aβ42 is modest (approxi-
mately 40%) and mostly absent for Aβ40 in the fibril
vaccinated group, while we observed a more robust (ap-
proximately 80%) decrease in plaque burden as deter-
mined by 6E10 immunoreactivity by IHC. The
explanation for this apparent discrepancy is not clear,
but it may be due to the fact that the ELISA measures
the amount Aß while the immunohistochemistry mea-
sures area of the plaque. This may be a reflection of a
change of state of the amyloid in the fibril vaccinated
group to a more compact or dense state rather than its
removal.
These results are consistent with recent findings that
vaccination against a random sequence peptide encoded
by read through of a stop codon in the pABri mRNA
improves cognition and reduces plaques in APP/PS1
mice [14]. Mice immunized with the ABri random
peptide produced antibodies that recognize aggregated
Aβ, reduced plaque deposition and improve cognition,
similar to the results we report here. However, the
immune response to this antigen is broader and includes
Figure 8 No increase in incidence of microhemorrhage in 3A and IAPP oligomer mimic vaccinated mice. A. Representative images of
Prussian blue stained sections. Arrowheads point to typical stage 1 microhemorrhages. Scale bar: 25 microns. B. The incidence of microhemorage
was counted after staining for hemosiderin. Both the Aß oligomer mimic and Aß fibril vaccinated groups display a much higher incidence of
microhemorrhage than the control, 3A or IAPP oligomer vaccinated groups. The mean counts from 3 different sections of each animal is shown
+/− the standard error of the mean (n = 8). ***P < 0.001. The 3A oligomer mimics and IAPP vaccinated group.
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plaques. Together with our results with the 3A random
sequence antigen, these results provide strong support
to the concept that targeting generic epitopes associated
with Aβ aggregates is therapeutically effective. Small but
significant levels of this type of antibodies exist in non-
vaccinated humans and the levels of these antibodies are
inversely correlated with the incidence of AD [38]. These
conformation-specific, sequence-independent antibodies
are the major antibodies against Aβ that exist in normal
human plasma [38] and these antibodies may account
for the reported effectiveness of IVIg in reducing the
incidence of AD in humans [39]. IAPP oligomer and
3A oligomer mimics vaccinated mice showed a rela-
tively low titer as compared to Aβ oligomer and Aβ
fibril vaccinated groups, yet retaining their efficacy in
preventing cognitive deficits and amyloid deposition.
Increasing evidence suggests a role for amyloid oligo-
mers as the toxic species responsible for disease pro-
gression and pathogenesis independently of the
plaque load [14]. In this view, our results suggest
that effective targeting of toxic species rather than
the overall extent of immune response elicited may
be relevant. The higher titer observed for either Aβ
oligomer and Aβ fibril vaccinated groups may there-
fore reflect the recognition of a broader range of
aggregated conformations.There is increasing evidence that Aβ oligomers and
fibrils are conformationally and structurally diverse [40-42],
which raises the issue of whether the different con-
formers are differentially associated with pathogenesis
[43]. Because monoclonal antibodies recognize these
conformers in a mutually exclusive fashion [44,45], a sin-
gle antibody may not be able to target all of the patho-
logically significant forms of Aβ. The polyclonal response
to active immunization is broad, suggesting that it
may be more beneficial in its ability to target more dif-
ferent conformers of Aβ than a single monoclonal [45].
A potential advantage of vaccination against conform-
ation dependent epitopes is that the resulting antibodies
are specific for aggregated forms of Aβ and do not react
with Aβ monomer or APP [13,40]. This suggests that
these antibodies may have a better pharmacological pro-
file than antibodies that recognize APP, which is abun-
dantly expressed or Aβ monomer which is a normal
product of APP processing and may have normal roles
that should not be interfered with. The lack of reactivity
with normal human proteins would also be expected to
provide a lower potential for autoimmune complications
as well.
We also found that the non-Aβ antigens, 3A and IAPP
were associated with a much lower incidence of micro
hemorrhage than the Aβ oligomer and Aβ fibril groups.
Since the conformation dependent immune response
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the immune response to the oligomer mimic antigens
is common [13,40], this suggests that the increased inci-
dence of micro hemorrhage may be due to sequence spe-
cific antibodies that are common to the Aß containing
antigens. This reduced incidence of micro hemorrhage
may also contribute to a superior safety profile of the
random sequence oligomer antigen, like 3A.
These results demonstrate that vaccination against gen-
eric amyloid oligomer epitopes is capable of attenuating
cognitive impairment and producing a protective immune
response without increasing the incidence of micro
hemorrhage, suggesting that vaccination against a non-
human amyloid oligomer epitope may be a safer thera-
peutic strategy for developing an effective vaccine that
circumvents auto inflammatory immune complications.
Materials and methods
Preparation of random peptides
We synthesized a series of 8 random sequence 20mers
using a restricted set of 8 amino acids, threonine, tyro-
sine, serine, histidine, isoleucine, valine, phenylalanine
and leucine. The sequences of the 20mers were ran-
domly drawn and checked against the human non-
redundant protein sequence data base with BLAST to
select for sequences that had the lowest homology with
human protein sequences. The sequences were syn-
thesized and tested for the ability to form prefibrillar
amyloid oligomers using the A11 prefibrillar oligomer
specific polyclonal antibody. One of the sequences (pep-
tide 3A: TYLIHVHIITIYHISIYYIV) formed A11 positive
oligomers in a time dependent fashion and was selected
for further analysis.
Oligomer mimic antigens
Aβ, IAPP and 3A peptide oligomer molecular mimic
antigens were prepared by synthesizing carboxyl-
terminal thiol derivatives and coupling them to colloidal
gold particles as previously described [46].
Preparation of Aβ prefibrillar oligomers and fibrils
Aβ40 peptides were lyophilized in 50% acetonitrile/
ddH2O. Soluble oligomers were prepared by dissolving
1.0 mg of peptide in 400ul hexafluoroisopropanol (HFIP)
for 10–20 min at room temperature. 100 μl of the result-
ing seedless solution was added to 900 μl milliQ H2O in
a siliconized Eppendorf tube. The samples were then
stirred at 500 RPM using a Teflon coated micro stir bar
for 24–48 h at 22°C. The samples were centrifuged
for 15 min. at 14,000 ×G and the supernatant fraction
(pH 2.8–3.5) was transferred to a new siliconized tube
and subjected to a gentle stream of N2 for 5–10 min to
evaporate the HFIP. Formation of oligomers were con-
firmed by atomic force microscopy (AFM), electronmicroscopy (EM) and size exclusion chromatography
(SEC) as described [40]. Fibrils were formed by dissolv-
ing Aβ42 in 50% HFIP/ddH2O and stirred with closed
caps for 7 days. Solution was stirred again for 2 days
using open caps to evaporate the HFIP. Fibrils were sedi-
mented, washed, and resuspended in PBS at 2 mg/ml.
Immunization
New Zealand white rabbits were immunized with 3A
oligomer mimics as previously described and the serum
collected after significant titer against Aβ oligomers was
detected [46]. Preimmune serum was collected from the
same rabbits prior to immunization. We immunized
young Tg2576 mice (3 months old) [5] with one of the
following antigens: Aβ oligomer, IAPP oligomer, Aβ
fibril, random peptide 3A oligomers or control with col-
loidal gold in PBS. The mice were equally distributed in
each group of eight (4 males and 4 females). The anti-
gens were mixed with incomplete Freund’s adjuvant (1:1,
v/v) and immunization was done subcutaneously
(100 μg/immunization) every month up to 14 months.
For controls a mixture of PBS and colloidal gold
was used.
Behavioral studies
Three common tests for cognitive dysfunctions in AD
model mice, the Morris Water Maze (MWM) [47,48]
novel-object recognition [48,49], and passive inhibitory
avoidance tests [10], were performed according to pre-
vious reports with minor modifications.
Morris water maze
Morris water maze is a special memory task related to
hippocampus. The apparatus used for all water maze
tasks was a circular aluminum tank (1.5 m diameter)
painted white and filled with water maintained at 26°C–
29°C. The maze was located in a room containing simple
visual, extra-maze cues. To reduce stress, mice were
placed on the platform in both the hidden and cued ver-
sions of the task for 15 sec. prior to the first training
trial. Mice were trained to swim to a circular clear Plexi-
glas platform (14 cm diameter) submerged 1.5 cm
beneath the surface of the water and invisible to the
mice while swimming. The platform location was
selected randomly at 14 months test, but was kept con-
stant for each individual mouse throughout training. On
each trial, the mouse was placed into the tank at one of
four designated start points in a pseudorandom order.
Mice were allowed 60 sec. to find the submerged plat-
form. If a mouse failed to find the platform within
60 sec., it was manually guided to the platform and
allowed to remain there for 15 sec. After this, each
mouse was placed into a holding cage under a warming
lamp for 30 s before beginning the next trial. To ensure
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learning, mice were given four trials a day for as
many days as were required to train the Tg2576 mice
to reach the criterion (<20 sec.). To control for over-
training, probe trials were run for each group, both
as soon as they reached group criterion and after all
groups had reached criterion. We trained the Tg2576
mice for 8 days at 14 months. Retention of the
spatial training was assessed 1.5 hr and again 24 hr
after the last training trial. Both probe trials con-
sisted of a 60 s free swim in the pool without the
platform. Mice were monitored by a camera mounted
in the ceiling directly above the pool to record the
1.5 hr and 24 hr test. The parameters measured dur-
ing the probe trial included initial latency to cross
the platform location, number of platform location
crosses, and time spent in the quadrant opposite to
the one containing the platform during training.Novel object recognition
The object recognition task used is based on the spon-
taneous tendency of rodents to explore a novel object
longer than a familiar one. On day 1, the mice were
allowed to familiarize themselves with the empty open
field for 5 minutes. On day 2, they were subjected to a
5-minute exploration session of two identical, symmet-
rically placed objects A. Ninety minutes and 24 hours
later, the animals were subjected to a 3-minute retention
session where they were exposed to one object A and to
a novel object B (after 90 minutes) or object C (after
24 hours). The times of exploration were recorded, and
an object recognition index (ORI) was calculated, such that
ORI= (tn - tf)/(tn + tf), where tf and tn represent times of
exploring the familiar and novel objects, respectively.Passive inhibitory avoidance
Amygdala dependent task was evaluated using the
passive inhibitory avoidance task [21], performed in
the Gemini Avoidance System (San Diego Instru-
ments, San Diego, CA). The training trial consisted
of placing a mouse in the illuminated compartment
of the device and recorded the latent time required
for the mouse to enter the dark compartment (base-
line latency). Upon entering the dark chamber, the
door between the two compartments was closed and
the animal was immediately given an electric shock
to the feet (0.15 mA, 1 s). During the retention trials
(conducted 1.5 h and 24 h after the training trial),
the mouse was again placed in the illuminated com-
partment and the latency to enter the dark compart-
ment was recorded. The retention trial was
interrupted if the animal took more than 180 sec-
onds to cross into the dark compartment.ELISA analysis of anti Aβ antibodies
ELISA assays were performed as previously described
[40]. Briefly, 200 ng/100 μl of antigen (Aβ oligomer,
IAPP oligomer, 3A oligomer mimic, Aβ fibril and Aβ
monomer) was plated on ELISA wells and blocked with
BSA. Serum samples were serially diluted to an end
point of 1:100,000. The secondary antibody used for de-
tection is peroxidase conjugated AffiniPure Goat Anti-
mouse IgG (H+L) (Jackson ImmunoResearch). Titer
was determined from the midpoint of the dilution curve
(IC50).Tissue collection and immunohistochemistry
After mice were anesthetized with pentobarbital
(150 mg/kg, IP), blood was collected by cardiac
puncture, and mice were perfused transcardially with
cold phosphate-buffered saline (PBS). Brain tissues
were fixed overnight with 4% paraformaldehyde in
PBS, pH 7.4 at 4°C and stored in PBS/0.02% sodium
azide (NaN3) at 4°C until use. Fixed brain tissues
were sectioned (40 μm) with a vibratome. Coronal
sections were collected in PBS (containing 0.02% so-
dium azide) and stored at 4°C prior to staining. To
stain for Aβ plaques, sections were immersed in 70%
formic acid for 5 min. Endogenous peroxidase in tis-
sue was blocked by treating with 3% H2O2 in PBS
for 10 min at room temperature. Nonspecific back-
ground staining was blocked by 1 h incubation in 2%
BSA, 0.3% Triton X-100 (TX) at room temperature.
Tissues were incubated with primary antibodies
(6E10, GFAP and CD45) overnight at 4°C, rinsed 3
times with PBS,0.1% TX, followed by biotinylated
secondary antibodies (anti-rabbit, anti-mouse and
anti-rat), detection with an ABC peroxidase kit, and
visualization with a 3,3'-diaminobenzidine (DAB) sub-
strate kit (Vector, Burlingame, CA). CD45 (Serotec, Ra-
leigh, NC; 1:3000) staining was done as described
previously [22]. Control experiments with primary or
secondary antibody omitted resulted in negative staining.Immunohistochemical analysis
Coronal brain sections were double-immunostained for
astrocytes and Aβ plaques. Sections were permeabilized
in 0.1% Triton X-100 for 15 min at RT, blocked in 5%
bovine albumin/PBS for 1 hour, and then probed with
anti-mouse glial fibrillary acidic protein, GFAP (1:1000,
Sigma), rabbit anti-fibril OC (1:4000) [13] for 24 h at
RT. Fluorescent-conjugated secondary antibodies (anti-
mouse, anti-rabbit Alexa, 1:400, Invitrogen Molecular
Probes) were used for detection. Double immunofluores-
cent images were captured at a magnification of 10x and
anayzed by the z-stack confocal microscopic system
using Axio Vision (Zeiss).
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Immunostaining was observed under a Zeiss Axiovert-
200 inverted microscope (Carl Zeiss, Thornwood, NY)
and images were acquired with a Zeiss Axiocam high-
resolution digital color camera (1300x1030 pixel) using
Axiovision 4.1 or 4.6 software. The same software (Carl
Zeiss) was used to analyze the digital images. Percent of
immunopositive area (% Field Area) (immunopositive
area/total image area × 100) was determined for all the
markers studied by averaging images of the cortex,
hippocampus and subiculum area from 2–3 sections per
animal. Digital images were obtained using the same set-
tings and the segmentation parameters constant within a
range per given marker and experiment. The mean value
of the% Field Area for each marker in each animal
was averaged per genotype group with the number of
animals per group indicated in Figure legends.
Enzyme-Linked Immunosorbent Assay (ELISA) for soluble
and insoluble Aβ
Soluble and insoluble Aβ fractions were isolated from
whole brain homogenates using four step extraction
protocol [24]. Frozen hemibrains were sequentially
extracted. At each step, sonication in an appropriate buf-
fer was followed by centrifugation at 100,000 x g for 1 hr
at 4°C. The supernatant was then removed, and the pel-
let was sonicated in the next solution used in the
sequential extraction process. For four-step extraction,
sonication of the frozen brain (150 mg/ml wet weight)
began in Tris-buffered saline (TBS) (20 mM Tris and
137 mM NaCl, pH 7.6), which contained protease inhi-
bitors (Protease inhibitor cocktail from Sigma St. Louis
USA). The next three sequential extraction steps used
1% Triton X-100 in TBS with protease inhibitors, 2%
SDS in water with the same protease inhibitors, and 70%
formic acid (FA) in water. Soluble fractions were loaded
directly onto ELISA plates, whereas insoluble fractions
were diluted 1:20 in a neutralization buffer (1 mol/L Tris
base, 0.5 mol/L NaH2PO4) before loading. MaxiSorp
immunoplates (Nunc, Rochester, NY) were coated with
Mab 20.1 antibody (a kind gift from Dr. David Cribbs
University of California Irvine) at a concentration of
25 μg/ml in coating buffer (0.1 M/L Na2CO3, pH 9.6)
and blocked with 3% bovine serum albumin. Standard
solutions for both Aβ40 and Aβ42 were made in the
antigen capture buffer (20 mmol/L NaH2PO4, 2 mmol/
EDTA, 0.4 M NaCl, 0.05% 3-[(3- cholamidopropyl)
dimethylammonio] propanesulfonate, and 1% bovine
serum albumin, pH 7.0) and loaded onto ELISA plates in
duplicate. Samples were then loaded (also in duplicate)
and incubated overnight at 4°C. Plates were then washed
and probed with either horseradish peroxidase conjugated
anti-Aβ40(C49) or anti-Aβ42(D32) overnight at 4°C. The
chromogen was 3,3_,5,5 tetramethylbenzidine, and thereaction was stopped by 30% phosphoric acid. The plates
were read at 450 nm using a plate reader (Molecular
Dynamics, Sunnyvale, CA). The readings were then nor-
malized to protein concentrations of the samples.
Micro hemorrhage analysis
Coronal brain sections were stained for hemosiderin as
previously described [18]. 3 different sections were counted
for each mouse and scored independently by two investiga-
tors as stage 1–4. Stage 1 is defined as “1 to 5 grains of iron
or small micro vessel involvement”; stage 2 is “multiple
grains of iron and micro vessel involvement”; Stage 3 is
“several positive micro vessels in 1 area”; and Stage 4 is
“large blood vessel involvement”. The data shown are the
averages of the two independent countings and are pre-
sented as the mean +/− the standard error of the mean.
Statistical analysis
All statistical analysis were performed using GraphPad
Prism 5 (GraphPad Software, San Diego, CA). For
comparison between antigen vaccinated groups and
control vaccinated group, one-way analysis of variance
(ANOVA) followed by Dunnet post-test was performed.
Probability values less than 0.05 were accepted as statis-
tically significant.
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